

NOVEL APPROACHES FOR SOLIDIFICATION OF SMEDDS

Swati Gokul Talele, V. R. Gudsoorkar
M. V. P. College of Pharmacy, Nasik, India.

Received on 04 Dec. 2015 Accepted on 20 March 2016 Available online from 10 April 2016

Abstract:

SMEDDS are isotropic mixtures of drug, oil, surfactant and co-surfactant that have unique ability of forming fine o/w micro-emulsion upon mild agitation followed by dilution in aqueous media, such as GI fluid. SMEDDS is the one of the approach to improve the solubility as well as the bioavailability of drug. There are different techniques used for conversion of liquid SMEDDS into solid SMEDDS such as spray drying, melt extrusion, adsorption to solid carrier, extrusion spheronisation, encapsulation of solid and semisolid SEDDS, etc. The present review highlights the various novel approaches for solidification of SMEDDS.

Keywords: SMEDDS, Bioavailability, Oil, Surfactant, Co-surfactant, Novel approaches

INTRODUCTION

Oral route is the least demanding, most advantageous course for non-invasive administration and the real course of drug delivery for the chronic treatment of numerous infections [1]. In current years, new chemical entities display poor aqueous solubility which thusly prompts low oral bioavailability⁽²⁾. Formulation of poorly aqueous soluble drugs is a testing employment to the pharmaceutical researchers as after effect of present day drug disclosure procedure and oral conveyance of such medications is much of the time connected with low bioavailability, high inters subject variability and absence of dosage proportionality [3-5]. The plan strategy assumes a vital part in defeating this weakness of inadequately water dissolvable medications, to experience these issues, different techniques are reported including utilization of surfactants, pulverization, crystal polymorphism determination, salt formation, solid dispersion, complex pulverization, complex development operators like cyclodextrin, emulsion, micro emulsion, liposome, molecule size, nanoparticles, small scale and Nano circles, lipids transporters, utilization of prodrug, medication derivatization, solution phase studies and penetration enhancers to enhance the disintegration

rate of the medication [6-10]. Lately, a considerable interest has given on lipid based definitions to upgrade the oral bioavailability of inadequately watery solvent medication mixes [11, 12]. Lipid formulation for oral administration consists of drug dissolved in oils, fractional glycerides, surfactants or co-surfactants. The primary system of activity which prompts enhanced bioavailability is generally maintain a strategic distance from the moderate disintegration process which constrains the bioavailability of hydrophobic medications from solid dosage forms [13,14]. The Self-Dispersing Lipid Formulations (SDLFs) is one of ways to deal with defeat the plan challenges of different hydrophobic medications and to enhance the oral bioavailability of poorly absorbed drugs. Figure 1 illustrates the oral drug absorption of self-emulsifying formulations from the GI mucosa to systemic circulation. It can also be changed into granules, pellets, powders for dry filled capsules or tablet preparations and also include into Ca-alginate microcapsules [15-18]. Approximately one third of the drugs present are poorly water soluble, causing several problems while developing formulations for such active pharmaceutical ingredients (API). According to the BCS Classification two classes shows poor aqueous solubility.

*Corresponding author E - mail: swatitalele77@gmail.com




Figure 1: SMEDDS improving bioavailability of drugs through oral absorption

SMEDDS

SMEDDS are defined as isotropic mixtures of drug, oil, surfactant and co-surfactant that have unique ability of forming fine o/w micro-emulsion upon mild agitation followed by dilution in aqueous media, such as GI fluid.




Figure 2: SMEDDS formulation

FORMULATION OF SMEDDS (Fig 2):

1. Oil :

Oils assume a basic part in S(M)EDDS on the grounds that it is in charge of solubilization of the hydrophobic medication, supporting in self-emulsification and in addition adds to the intestinal lymphatic transport of the medication. The emulsification property of the oil is said to be subject to the sub-atomic structure of the oil [7].

2. Surfactant :

Surfactants are surface dynamic atoms which assemble at the oil-water interface and settle the inner stage in an emulsion. Surfactants are basic parts of S(M)EDDS frameworks since they are in charge of shaping a steady emulsion upon aqueous dilution. Surfactant molecules can be classified based on the nature of hydrophilic group within the molecule. The usual surfactant strength ranges between 30-60% w/w of the formulation in order to form a stable SMEDDS.

3. Co-Surfactant

Water solvent co-surfactants are generally utilized as a part of lipid based dose frames. Ethanol, polyethylene glycol (PEG), propylene glycol, and glycerol are illustrations of co-surfactants utilized.

Table 1. Some Excipients used in SMEDDS

Oil	Surfactant	Co-Surfactant
Maisine	Tween 80	Ethanol
Oleic Acid	Cremophore EL	PEG 400
Rice Bran Oil	Span 80	Propylene Glycol
Clove Oil	Labrasol	Transcutol
Olive Oil	Lauroglycol -FCC	Capryol 90
Groundnut Oil	Lauroglycol 90	Gelucire
Soyabean Oil	Tween 20	Capryol PGMC
Sunflower Oil	Cremophor RH 40	PEG 300
Arachis Oil	Cremophor RH 60	PEG 600
Labrafac Lipophile WL	Labrafil M-1944CS	Propyleneglycol - dicaprylate/ dicaprate

The segments for further study were chosen relying upon the most extreme medication solvency in oil stage, surfactant and co-surfactant and capacity of self-emulsification of these vehicles with one another for specific blend. Along these lines, suitable mix chose and tests were readied with diverse extents of oil, surfactant and co-surfactant with the proportions of oil : (surfactant and co-surfactant i.e. S blend) as 1:9, 2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2, 9:1. The S blend proportions of 1:1, 2:1, 3:1, 1:2 and 1:3 were assessed (Table 1).

Pseudo Ternary Phase Diagram Construction:

Pseudo-ternary phase diagram of oil, surfactant/co-surfactant (Smix) and water were created utilizing the water titration system. The blends of oil and Smix at certain weight proportions were diluted with water in a dropwise way. For each phase diagram at a particular proportion of Smix (i.e., 1:1, 2:1, 3:1, 1:2 and 1:3 w/w), straightforward and homogeneous blends of oil and Smix in proportion 1:9 to 9:1 w/w were prepared and

shake for 5 minutes. At that point every blend was titrated with water and outwardly watched for stage clarity and flowability. The concentration of water at which turbidity-to-transparency and transparency-to-turbidity transitions occurred was derived from the weight measurements. These qualities were then used to decide the limits of the microemulsion space relating to the chosan estimation of oils and in addition Smix blending proportion. The pseudo ternary stage outlines were plotted with the assistance of CHEMIX Software (figure 3).

CHARACTERIZATION & EVALUATION of SMEDDS

The primary means of self-microemulsification assessment is visual evaluation. The efficiency of self-microemulsification could be estimated by determining the rate of microemulsification, droplet size distribution and turbidity measurement.

Droplet size and particle size measurement: The molecule size of the micro emulsion is dictated by photon correlation spectroscopy or SEM (Scanning Electron Microscopy) which can measure sizes somewhere around 10 to 5000 nm [23, 24].

Refractive index and percent transmission: Refractive index and percent transmittance demonstrates the clearness of plan. The refractive record of the SMEDDS




Figure 3: Pseudo Ternary Phase Diagram

is measured by refractometer. The percent transmittance is measured at specific wavelength utilizing UV-Vis spectrophotometer keeping distilled water as clear. In the event that refractive index is to be like that of water. Detailing indicating transmittance >99 percent is transparent in nature [25, 26].

Determination of percentage drug content: One capsule of every formulation was taken in a 100 mL volumetric flask, and added 100 mL of extracting solvent. At that point blend was shaken for 1 h in mechanical shaker and kept aside for 24 h. After 24 h, separated the arrangement through Whatman filter paper (0.45 μm) to gather the filtrate. The filtrate was then investigated in UV spectrophotometer. The percent drug content was then determined using absorbance and standard graph [26].

Phase separation study: One milliliter SMEDDS was added to glass test tube containing 5 mL of 0.1 N HCL, buffer pH 6.8 and distilled water. After altering the test tube for 3-4 times, every blend was put away for a time of 2h and phase separation was observed visually [27].

Dispersibility test: The productivity of self-emulsification of oral micro/Nano-emulsions is measured by utilizing a standard USP dissolution apparatus. To 500 mL of water 1 mL of the formulation is to be included at $37\pm 0.5^\circ\text{C}$. A standard stainless steel dissolution paddle rotating at 50 rpm gives gentle agitation. The in vitro study of the formulation is outwardly evaluated from such a dispersion using a suitable grading system. Grading system can be based upon the arrangement of a micro emulsion (o/w or w/o), micro-emulsion gel, emulsion, or emulgel.

Zeta potential measurement: Zeta potential for micro emulsion can be determined using a suitable Zeta sizer, in triplicate samples [28].

Cloud point measurement: Cloud point temperatures (T_c) were dictated by visual perception. 0.5 ml of concentrate was weakened to 50mL with distilled water in glass receptacle. The specimen was warmed at the rate of $0.5^\circ\text{C}/\text{min}$. A nearby perception was shown up of the scattering with the increment in temperature. The temperature at which the dispersion becomes

cloudy was taken as T_c . After the temperature exceeds the cloud point, the sample was cooled below T_c , and then it was heated again to check the reproducibility of the measurements [29].

Effect of drug loading on droplet size: Effect of drug loading on globule size of micro-emulsion was studied using optimized composition formulation were prepared with or without drug. The resultant SMEDDS concentrate, 0.5 mL was diluted to 100 mL with double distilled water and the mean globule size of the subsequent small scale emulsion was controlled by Motic computerized Microscope(model:UMWBL-233ASC, Mumbai) [29].

Effect of dilution in different media: Dilution study was done to get to the impact of dilution on SMEDDS concentrate, with a specific end goal to imitate physiological dilution procedure after oral administration. In this study chosen plan were subjected to expanding dilution (i.e. 10 and 100times) and different diluents i.e. double distilled water, simulated gastric liquid (SGF), simulated intestinal liquid (SIF). Visual perception were recorded and evaluated according to review [29].

Thermodynamic stability study: The objective of thermodynamic stability is to evaluate the phase separation and effect of temperature variation on SMEDDS formulation. SMEDDS were diluted with aqueous medium were centrifuged at 15,000 rpm for 15 min and then observed visually for phase separation. Further formulation were subjected to freeze thaw cycles (-20°C for 2 days followed by $+40^\circ\text{C}$ for 2 days) and were observed for appearance, phase separation. ⁽²⁹⁾

Stability: SMEDDS was diluted with distilled water and to check the temperature stability of samples, they were kept at two diverse temperature range ($2-5^\circ\text{C}$ (cooler), room temperature) and watched for any proofs of stage division, flocculation or medication precipitation [30].

***In-vitro* Lipolysis Study**

In vitro lipolysis tests were conducted utilizing as a part of in-vitro lipid digestion model with a pH-Stat

programmed titration unit (848 Titrino in addition, Metrohm AG, Herisau, Switzerland). The lipolysis of SMEDDS and oil arrangement (MCT, ethyl oleate, and castor oil) were resolved in independent trials. For

was tied with cellophane layer and plunged in support arrangement kept in a receptacle beneath. Upper side of the chamber was supported to hold. The measuring glass was constantly blended by stirrer and




Figure 4: Factors affecting SMEDDS Formulation

every examination, 1 g of SMEDDS (or 0.4 g of oil arrangement) was included into a thermostated response vessel and scattered in 18 mL of processing cradle (50 mM Trizma maleate, 150 mM NaCl, 5 mM $\text{CaCl}_2 \cdot 2\text{H}_2\text{O}$, pH 7.5) containing 5 mM NaTC (sodium taurocholate) and 1.25 mM PC. The pH was then changed in accordance with 7.5 with 0.1 M NaOH. The processing tests were started by the expansion of 1 mL of pancreatin concentrate and the blend was kept at 37°C with persistently mixing.

In-vitro release study: In vitro medication discharge investigation of SMEDDS definition was performed by dialysis technique, dissolution apparatus 2 and diffusion cell. Investigation of drug release was finished by changed dispersion cell in 200 mL buffer solution 6.4 pH. One gram SMEDDS plan was set in boiling tube, both side of boiling tube was opened and one side of tube

test was pulled back after sufficient time intervals in straight position and investigated by UV Spectrophotometer Percent medication disintegrated at distinctive time intervals was computed utilizing the beer lamberts mathematical statement.

CONVERSION OF LIQUID SMEDDS TO SOLID SMEDDS

Liquid SEDDS can be filled in soft or hard gelatin capsule. Recently, there have been efforts by research groups working on SEDDS to convert liquid SEDDS to solid state SEDDS. These Solid SEDDS can be made into tablets or be encapsulated. The primary reason to formulate SEDDS in a solid form is to consolidate the advantages of Liquid SEDDS with convenience of solid oral dosage forms.

Oral solid dosage forms have the following advantages [35]:

- (a) Low production cost
- (b) Convenience of process control
- (c) High stability and reproducibility and
- (d) Better patient compliance.

Spray drying:

Spray drying is the most broadly utilized strategy to change over Liquid SEDDS into solid state. In this system the Liquid SEDDS is blended with a strong transporter in a suitable solvent. The solvent is then atomized into a shower of fine beads. These beads are brought into a drying chamber, where the solvent gets vanished framing dry particles under a controlled temperature and conditions [35]. The dry particles can then be either filled into cases or made into tablets after expansion of suitable excipients. Different strong transporters that have been utilized for this intention are: Aerosil 200 suspended in ethanol [35] and fluid arrangement of Dextran 40 [37].

Adsorption to solid carriers:

The Liquid SEDDS can be made to adsorb onto free streaming powders that have vast surface region and are fit for adsorbing high amounts of oil material. The adsorption should be possible either by blending Liquid SEDDS and the adsorbent in a blender or by basic physical blending. The subsequent powders can be either filled into cases or can be made into tablets after expansion of suitable excipients. The adsorbents are equipped for adsorbing Liquid SEDDS up to 70 %w/w of its own weight. Strong transporters utilized for this reason can be micro-porous inorganic substances, high surface range colloidal inorganic substances or cross-linked polymers [35]. Classes of strong adsorbents utilized are: silicates, magnesium trisilicate, talcum, crospovidone, cross-linked sodium carboxy methyl cellulose and cross-linked polymethyl methacrylate⁽³⁸⁾. Oral strong heparin and gentamicin SMEDDS were prepared utilizing three sorts of adsorbents: microporous calcium silicate (Florite RE), magnesium aluminosilicate (Neusilin US2) and silicon dioxide (Sylysia 320) [39,40].

Encapsulation of Liquid and Semisolid SEDDS:

It is one of the most straightforward strategies for transformation of Liquid SEDDS to strong oral measurement structure. Fluid SEDDS can be basically filled in cases, fixed utilizing a micro spray. For a semisolid SEDDS, it is a four stage process: (1) warming the semisolid excipients to not less than 20°C over its liquefying point; (2) including the medication in the liquid blend while mixing; (3) filling the medication stacked liquid blend into the case shell and (4) cooling the item to room temperature. Lipid excipients perfect with the container shell are depicted in the work by Cole et al [41].

Extrusion Spheronization:

This is a solvent free strategy that changes over Liquid SEDDS into pellets utilizing expulsion and spheronization forms. In this technique the Liquid SEDDS is initially blended with a mass moved slowly by expansion of water until the mass is suitable for expulsion. The expelled mass is then spheronized to formulate uniform measured pellets. The pellets are then dried and size isolated. The relative amount of water and Liquid SEDDS utilized as a part of the procedure affects size conveyance, expulsion power, surface roughness of pellets, and disintegration time [42]. Abdalla et al. utilized microcrystalline cellulose (MCC) as content in planning of progesterone self-emulsifying pellets⁽⁴³⁾. A blend of silicon dioxide, glyceryl behenate, pregelatinized starch, sodium cross carmellose, and MCC were utilized by Setthacheewakul et al. in the readiness curcumin stacked SMEDDS pellets [44].

Melt Granulation:

Melt Granulation is another solvent free strategy for changing over Liquid SEDDS. In this system, Liquid SEDDS is blended with a folio that melts or softens at moderately low temperature. This dissolved blend can be granulated. This system is invaluable since it doesn't require expansion of a fluid fastener and resulting drying dissimilar to ordinary wet granulation. The variables to be controlled in this procedure are impeller velocity, blending time and fastener molecule size [35].

A blend of mono-, di- and triglycerides and esters of polyethylene glycol (PEG) called as Gelucire are utilized as fasteners to get ready prompt discharge pellets by melt granulation and as a self-emulsifying drug delivery system by capsule moulding or as powder obtained by cryogenic grinding [45].

NOVEL APPROACHES FOR SOLIDIFICATION OF SMEDDS:

Dry emulsion: Dry emulsions are powdered solid dosage forms which suddenly emulsify with the expansion of water. Dry emulsions could be acquired by emulsifiable glass system, freeze drying, and spray drying. Lipid based surfactant free emulsifiable glass framework was produced by Myers et al [46]. In this strategy an ineffectively water solvent medication broke up in a vegetable oil is blended with watery arrangement of sucrose. The blend is then vanished under vacuum delivering dry froth. This dry froth creates an emulsion when added to water. Endeavors have been made to convey cyclosporin A by means of strategy [47]. Stop drying of oil-in-water emulsions utilizing hazy cryoprotectants was portrayed by Bamba et al [48]. Vyas et al. arranged dry emulsion of griseofulvin utilizing mannitol as the cryoprotectant [49]. Corveleyn et al. considered parameters influencing the planning of lyophilized dry emulsion tablets [50]. Dry emulsion of Amlodipine was created by splash drying of an emulsion utilizing dextrin as a bearer [51]. Toorisaka et al created an enteric covered dry emulsion for the conveyance of peptides and proteins [52].

Capsules: Solid S(M)EDDS arranged by different systems specified above can be filled into capsule shells. This prevents physical incompatibility of Liquid S(M)EDDS with the capsule shell. If semi-solid excipients are used in the formulation, they are first melted and then filled into capsules. Contents of the capsule then solidify at room temperature.

Tablets: Nazzal et al. [53] detailed eutectic based self-emulsifying tablets in which irreversible precipitation of the drug within the formulation was inhibited. Aeutectic framing mixture of a drug and suitable semi-solid oil was used as a part of the process. Using the melting point depression method the oil phase containing the

drug melts at body temperature producing emulsion droplets in the nanometer size range. During planning of such tablets maltodextrin, changed povidone, and microcrystalline cellulose (MCC) were utilized as extra excipients. The medication discharge from such tablets can be maintained by adjusting the molecule size of MCC.

Pellets: Pellets are convenient multiple unit dosage forms, which are made by extrusion/spheronization technique mentioned previously.

Solid dispersions: Accessibility of self-scattering waxy semi-solid excipients have decreased the assembling and strength issues connected with strong scatterings. Excipients, for example, Gelucire 44/14 and Gelucire 50/02 are utilized for this reason. These are semisolid excipients which can be straightforwardly filled into containers in a liquid state. Gelucire have high surface movement which improves disintegration of ineffectively water solvent medications. Assimilation of medication is likewise enhanced when Gelucire is utilized as a part of strong scattering [54]. The bioavailability of an investigational compound was accounted to have improved utilizing Gelucire 44/14 with respect to PEG based detailing.

Beads: Patil et al. used porous polystyrene beads for delivering self-emulsifying formulations. The formulation is incorporated into microchannels of the bead through capillary action. The beads were prepared by copolymerizing styrene and divinyl benzene [55].

Microspheres: Sustained release microspheres of Zedoary turmeric oil (traditional Chinese medicine) were prepared by a quasi-emulsion-solvent-diffusion method. The microspheres reported in this research work were made using hydroxypropyl methyl cellulose acetate succinate and Aerosil 200 [56].

Nanoparticles: Self-emulsifying nanoparticles can be formulated using solvent injection technique, wherein the excipients and medication are softened together and infused into a nonsolvent. The nanoparticles can be isolated by centrifugation and lyophilization. Self-emulsifying nanoparticles of drugs were prepared using goat fat and Tween 65 using this method [57]. Glyceryl

monooleate (GMO) which has self-emulsifying property was utilized alongside chitosan for arrangement of paclitaxel nanoparticles. Chitosan was in charge of bioadhesion of nanoparticles, while 100% medication fuse was accomplished due to self-emulsifying property of GMO [58].

Implants: Hae, G.S., et al. Studied self-emulsified 1, 3-bis (2-chloroethyl)-1-nitrosourea (carmustine, BCNU) which was incorporated into PLGA (poly(lactic-co-glycolic acid)) and used as an implant. The SEDDS formulation retarded the exposure of BCNU from the aqueous media and thus improved its stability and shelf life. The formulation comprised of tributyrin, cremophor RH 40, Labrafil 1944 and BCNU [59].

Suppositories: Hae, G.S., et al. Studied Glycerrhizin self-emulsifying suppositories which were formulated using C6-C18 fatty acid glycerol ester and C6-C8 fatty acid macrogol ester. The formulation demonstrated good drug absorption as indicated by high plasma drug levels when delivered via rectal/vaginal route [59].

Self-Microemulsifying Mouth Dissolving Film

Xiao L, et al., developed another self-microemulsifying mouth dissolving film (SMMDF) for inadequately water-soluble drug, for example, indomethacin was produced by fusing self-microemulsifying segments with solid carriers for the most part containing microcrystalline cellulose, low-substituted hydroxypropyl cellulose and hypromellose. The consistency of measurements units of the planning was worthy as per the criteria of Chinese Pharmacopeia 2010. The SMMDF was break inside for 20 s after mixing with water, discharged totally at 5 min in the disintegration medium and accomplished micro-emulsion molecule size of 28.81 ± 3.26 nm. Solid state structure of the SMMDF was performed by SEM, DSC and X-ray powder diffraction. Results exhibited that indomethacin in the SMMDF was in the unclear state, which may be because of self-micro-emulsifying fixings. Pharmacokinetic parameters in rats including T max, Cmax, AUC were comparable between the SMMDF and fluid SMEDDS. AUC and Cmax from the SMMDF were significantly higher than those from the normal mouth dissolving film or the ordinary

tablet, and T max from SMMDF gathering was likewise essentially diminished. These findings recommend that the SMMDF is another promising dose structure, demonstrating remarkable attributes of accommodation, speedy onset of activity and upgraded oral bioavailability of poorly water-soluble drugs.

Herbal self micro-emulsifying drug delivery system (SMEDDS)

The present investigation was aimed at developing a stable self-micro emulsifying drug delivery system (SMEDDS) of herbal extract and evaluating its in vitro potential. SMEDDS provides liquids filled a hard gelatin capsule which has been an option for this herbal extract developing stable and safe dosage forms. The solubility of herbal extract was determined in various vehicles. Pseudo ternary phase diagrams were used to evaluate the micro emulsification existence area. Release rate of herbal extract was investigated using a dissolution method. SMEDDS were characterized for clarity, precipitation and particle size distribution. Formulation development and screening was done based on results of solubility and from phase diagram. Samiksha Warke et al used the optimized formulation for in vitro dissolution which was composed of herbal extract (30 %), Cremophor RH 40 (40 %), Plurol Oleique (30%). The SMEDDS formulation showed complete release in 10 min. as compared with the plain extract and conventional marketed formulation with limited dissolution rate. SMEDDS were subjected to various conditions of storage as per ICH guidelines for 3 months. SMEDDS successfully withstood the stability testing. It has been found that dissolution profile of herbal extract from SMEDDS was much improved. SMEDDS appeared to be an interesting approach to improve solubility, and ultimately bioavailability.

Lecithin-linker formulations for self-emulsifying delivery of nutraceuticals

Chu J, et al., studied lecithin-linker micro emulsions which is the process delivered with soybean lecithin in blend with a lipophilic linker and hydrophilic linkers. In this, lecithin-linker creates self-emulsification with β -carotene and β -sitosterol. The grouping of the lipophilic

linker, sorbitan monooleate, was acclimated to minimize the development of fluid precious stones. The grouping of hydrophilic linkers, decaglyceryl caprylate/caprinate and PEG-6-caprylic/capric glycerides, was steadily expanded (checked) until clear microemulsions were formed. For these outputs, the oil (ethyl caprate) to water proportion was set to 1. The single stage, clear micro-emulsions were weakened and created stable emulsions, with droplet size near 200 nm. Utilizing pseudo-ternary stage charts to assess the procedure of weakening of microemulsion pre-concentrates (blends of oil, lecithin and linkers with practically no water) with FeSSIF (Fed-State Simulated Intestinal Fluid), it was resolved that self-emulsification are acquired when the early phases of the weakening produce single stage microemulsions. The numerous stage are acquired to avoid those early stages, then the emulsification yields insecure emulsions with substantial drop sizes. An in vitro porousness study directed utilizing a Flow-Thru Dialyzer uncovered that steady emulsions with drop sizes of 150–300 nm create substantial and irreversible permeation of b-carotene to sheep digestive system. Then again, precarious emulsions created without the linker mix isolated in the dialyzer chamber.

Sponges Carrying Self-microemulsifying Drug Delivery Systems

Elinor Josef, et al., studied self-microemulsifying drug delivery systems (SMEDDS) build the solvency of lipophilic medications. One boundary to their wide application is their fluid nature. This is a new technique for formulation of SMEDDS—their incorporation in sponges made from a hydrophilic regular polymer. The nanosponge structures were concentrated on with examining electron microscopy and little edge X-beam diffusing. The oil beads survived the drying procedure, and SMEDDS were available as 9 nm-sized objects in the dried sponges. The sponges were rehydrated in water, and confirmation of the presence of SMEDDS in the rehydrated sponges was found. A model hydrophobic particle, Nile red, was solvent in all dry and rehydrated

sponges. SMEDDS containing Nile red were drop by drop discharged from the nanosponges, at a rate that depend upon the drying technique. The water uptake of the nanosponges was additionally found to be impacted by the drying plan. The blend of SMEDDS and sponges may be an approach to beat the drawbacks of every part independently, give a strong measurements structure for SMEDDS that can manage the arrival of medications furthermore empower usage of hydrophilic sponges for the conveyance of hydrophobic medication.

CONCLUSION

Some of the concealed features of Self-micro emulsifying drug delivery systems (SMEDDS) have been revealed by the literature review. SMEDDS is a promising drug delivery system for the enhancement and improvement of bioavailability for a hydrophobic drug. This review article will definitely drag the attention of the young researchers to understand the role of individual lipids and surfactants used for the formulation of SMEDDS as lipid based formulations are still not very widespread as commercial formulations. Also this study explores the possibilities of loading a wide variety of hydrophobic drugs and plant actives as their scale up is convenient as well as economical too.

REFERENCES

1. Reddy, L.H. and RS. Murthy, 2002. Lymphatic transport orally administered drugs. *Indian J. Exp. Boil.*, 40: 1097-1109.
2. Robinson, J.R, 1996. Introduction: Semi-solid formulations for oral drug delivery. *Bull. Tech, Gattefosse*, 89: 11-13.
3. Dey, P., S.Maiti, S.Ray, B.Sa and K.Sen, 2009. Self-emulsification of poorly soluble and highly permeable drugs: An overview. *Int. J. Pharm. Recent Res.*, 1:67-72.
4. Kanika, S., Y.Pawar, B.Bansal and K Arvind, 2010. Self-emulsifying drug delivery system: A Strategy to Improve Oral Bioavailability. *Current Res. Inform. Sci.*, 3:42-49.

5. Giri, T.K, H. Badwaik, A Alexander and D.K Tripathi, 2010b. Solubility enhancement of ibuprofen in the presence of hydrophilic polymer and surfactant. *Int. J. Applied Bio I. Pharm. Technol.*, 1:793-800.
6. Mandal, S. and S.S.Mandal, 2011. Microemulsion drug delivery system: A platform for improving dissolution rate of poorly water soluble drug. *Int. J. Pharm. Sci. Nanotechnol.*, 3:1214-1219.
7. Badawi, A.A., M.A.El-Nabarawi, D.A.El-Setouhy and S.A. Alsammit, 2011. Characterization and stability testing of itraconazole solid dispersions containing crystallization inhibitors. *Am. J. Drug Discovery Dev.*, 1:144-159.
8. Seedher, N. and P.Sharma, 2007. Solubility and stability enhancement of poorly-soluble drugs clarithromycin and prednisolone by combination with other drugs. *Int. J. Biol. Chem*, 1:229-236.
9. Wanwimolruk, S., J.R. Denton, D.G. Ferry, M.Beasley and J.R. Broughton, 1992. Polymorphism of debrisoquine oxidation in New Zealand Caucasians. *Eur. J. Clin. Pharmacology*. 43:349-350.
10. Amarji, B., Ajazuddin, D. Raghuwanshi, S.P. Vyas and P. Kanaujia, 2007. Lipid nano spheres (LNSs) for enhanced oral bioavailability of amphotericin B: Development and characterization. *J. Biomed. Nanotechnology*. 3:264-269.
11. Burcham, D.L., M.B. Maurin, E.A. Hausner and S.M. Huang, 1997. Improved oral bioavailability of the hypocholesterolemic DMP 565 in dogs following oral dosing in oil and glycol solutions. *Biopharm. Drug Dispos*. 18:737-742.
12. Patel, M., S.Patel, N. Patel and M. Patel, 2011. A review: Novel oral lipid based formulation for poorly soluble drugs. *Int. J. Pharm. Sci. Nanotechnol.*, 3:1182-1192.
13. Pouton, C.W., 2000. Lipid formulations for oral administration of drugs: non-emulsifying, self-emulsifying and self-microemulsifying drug delivery systems. *Eur. J. Pharm. Sci.*, 11:S93-S98.
14. Tang, J.L., J. Sun and Z.G. He, 2007. Self-emulsifying drug delivery systems: Strategy for improving oral delivery of poorly soluble drugs. *Curro Drug Ther*. 2:85-93.
15. Nazzal, S. and M.A Khan, 2006. Controlled drug release of a self-emulsifying formulation from a tablet dosage form: Stability assessment and optimization of some processing parameters. *Int. J. Pharm.*, 315: 110-121.
16. Abdalla, A., S.Klein and K Mader, 2008. A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: Characterization, dissolution, invitro digestion and incorporation into solid pellets. *Eur. J. Pharm. Sci.*, 35:457-464.
17. Serraton, M., M. Newton, S. Booth and A Clarke, 2007. Controlled drug release from pellets containing water-insoluble drugs dissolved in a self-emulsifying system. *Eur. J. Pharm. Bio pharm.*, 65:94-98.
18. Tan, A., S. Simovic, A.K Davey, T. Rades and C.A. Prestidge, 2009. Silica-lipid hybrid (SLH) microcapsules: A novel oral delivery system for poorly soluble drugs. *J. Control. Release*, 134: 32-70.
19. Patel, V.P., T.R.Desai, P.P. Kapupara, S.A Atara and RA Keraliya, 2010b. Self emulsifying drug delivery system: A conventional and alternative approach to improve oral bioavailability of lipophilic drugs. *Int. J. Drug Dev. Res.*, 2:859-870.
20. Kim, H.J., KA. Yoon, M.Hahn, E.S. Park and S.C. Chi, 2000. Preparation and In Vitro evaluation of self-microemulsifying drug delivery systems containing idebenone. *Drug Dev. Ind. Pharm.*, 26: 523-529.
21. Gershanik, T., E. Haltner and S.Benita, 2000. Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. *Int. J. Pharm.*, 211: 29-36.
22. Gershanik, T. and S.Benita, 2000. Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. *Eur. J. Pharm. Biopharm.*, 50:179-188.
23. Rad, AS., 2010. Study on preparation and some properties of panretin-loaded nanocapsules. *Biotechnology*, 9:234-237.
24. Ramachandran, S., G. Thirumurugan and M.D. Dhanaraju, 2011. Development and evaluation of biodegradable chitosan microspheres loaded with

- ranitidine and cross linked with glutaraldehyde. *Am. J. Drug Discovery Dev.*, 1:105-120.
25. Patil, P., P. Joshi and A Paradkar, 2004. Effect of formulation variables on preparation and evaluation of gelled Self-Emulsifying Drug Delivery System (SEDDS) of ketoprofen. *AAPs PharmSci. Tech.*, 5:43-50.
 26. Patil, P., V.Patil and A Paradkar, 2007. Formulation of a self-emulsifying system for oral delivery of simvastatin: In vitro and In vivo evaluation. *Acta Pharm.*, 57: 111-122.
 27. Kim, J.Y. And Y.S. Ku, 2000. Enhanced absorption of indomethacin after oral or rectal administration of a self-emulsifying system containing indomethacin to rats. *Int. J. Pharm.*, 19:81-89.
 28. Abbasalipourkabir, R., A. Salehzadeh and R. Abdullah, 2011. Cytotoxicity effect of solid lipid nanoparticles on human breast cancer cell lines. *Biotechnology*, 10:528-533.
 29. Shilpa P Chaudhari, Sadhana Kolhe, A.A. Ranpise and M.P.Ratnaparkhi, 2013, Design and Development of Oral Lipid Based Solid Self Micro-emulsified Drug Delivery System, 3(4): 570-586. 3
 30. Ghosh, P.K, M.L. Umrethia and R.J. Majethiya, 2004. Preparation and Physicochemical characterisation of caprylocapryl macrogol-8-glycerides microemulsion for oral drug delivery. *Ars. Pharm.*, 45:353-372.
 31. Kallakunta VR, Bandari S, Jukanti R, Reddy P, Reddy V. Oral self-emulsifying powder of lercanidipine hydrochloride: Formulation and evaluation. *Powder Technol.* 2012; 221:37582.
 32. Balakrishnan P, Lee BJ, Dong Hoon Oh, Jong Oh Kim, Myung J Hong, Jun-Pil Jee. Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). *Eur J Pharm Biopharm* 2009; 72:539-545.
 33. Balakrishnan P, Beom-Jin Lee, Dong Hoon Oh, Jong Oh Kim, Young-Im Lee, Dae-Duk Kim, Jun-Pil Jee, Yong-Bok Lee, Jong SooWoo, Chul Soon Yong, Han-Gon Choia. Enhanced oral bioavailability of Coenzyme Q10 by self-emulsifying drug delivery systems. *Int J Pharm* 2009; 374:66-72.
 34. Bandivadekar MM, Pancholi SS, Shelke N. Preparation and characterization of solid self-micro emulsifying drug delivery system by adsorbent technique to improve dissolution profile of poorly aqueous soluble drug Ramipril. *Int Res J Pharm* 2011; 2(6): 85-90.33
 35. Tang, B., et al., Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. *Drug Discovery Today*, 2008. **13**(13- 14): p. 606-612.
 36. Balakrishnan, P., et al., Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). *European Journal of Pharmaceutics and Biopharmaceutics*, 2009. **72**(3): p. 539-545.
 37. Yi, T., et al., A new solid self-microemulsifying formulation prepared by spray drying to improve the oral bioavailability of poorly water soluble drugs. *European Journal of Pharmaceutics and Biopharmaceutics*, 2008. **70**(2): p. 439- 444.
 38. Carli, F. and E. Chiellini, Pharmaceutical composition comprising a water/oil/water double microemulsion incorporated in a solid support. 2004, Google Patents.
 39. Ito, Y., et al., Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. *International journal of pharmaceutics*, 2006. **317**(2): p. 114-119.
 40. Ito, Y., et al., Oral solid gentamicin preparation using emulsifier and adsorbent. *Journal of Controlled Release*, 2005. **105**(1-2): p. 23-31.
 41. Cole, E.T., D. Cadé, and H. Benameur, Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. *Advanced Drug Delivery Reviews*, 2008. **60**(6): p. 747-756.3
 42. Fanun, M., *Colloids in Drug Delivery*. 2010, CRC Press.
 43. Abdalla, A., S. Klein, and K. Mäder, A new self-emulsifying drug delivery system (SEDDS) for poorly soluble drugs: Characterization, dissolution, in vitro digestion and incorporation into solid pellets. *European journal of pharmaceutical sciences*, 2008. **35**(5): p. 457-464.

44. Setthacheewakul, S., et al., Development and evaluation of self-microemulsifying liquid and pellet formulations of curcumin, and absorption studies in rats. *European Journal of Pharmaceutics and Biopharmaceutics*, 2010.
45. Chambin, O., et al., Influence of cryogenic grinding on properties of a self-emulsifying formulation. *International journal of pharmaceutics*, 2004. **278**(1): p. 79-89.
46. Myers, S.L. and M.L. Shively, Preparation and characterization of emulsifiable glasses: Oil-in-water and water-in-oil-in-water emulsions. *Journal of colloid and interface science*, 1992. **149**(1): p. 271 - 278.
47. Porter, C.J.H., et al., Evaluation of emulsifiable glasses for the oral administration of cyclosporin in beagle dogs. *International journal of pharmaceutics*, 1996. **141**(1-2): p. 227-237.
48. Bamba, J., et al., Cryo-protection of emulsions in freeze-drying: freezing process analysis. *Drug development and industrial pharmacy*, 1995. **21**(15): p. 1749-1760.
49. Vyas, S., et al., Preparation and characterization of griseofulvin dry emulsion. *Pharmazie*, 1992. **47**(6): p. 463-464.
50. Corveleyn, S. and J.P. Remon, Formulation of a lyophilized dry emulsion tablet for the delivery of poorly soluble drugs. *International journal of pharmaceutics*, 1998. **166**(1): p. 65-74.
51. Jang, D.J., et al., Improvement of bioavailability and photostability of amlodipine using re-dispersible dry emulsion. *European journal of pharmaceutical sciences*, 2006. **28**(5): p. 405-411.
52. Toorisaka, E., et al., An enteric-coated dry emulsion formulation for oral insulin delivery. *Journal of Controlled Release*, 2005. **107**(1): p. 91 -96.
53. Nazzal, S., et al., Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. *International journal of pharmaceutics*, 2002. **235**(1-2): p. 247-265.
54. Hauss, D., Oral lipid-based formulations. *Advanced Drug Delivery Reviews*, 2007. **59**(7): p. 667-676.
55. Patil, P. and A. Paradkar, Porous polystyrene beads as carriers for self-emulsifying system containing loratadine. *AAPS Pharm Sci Tech*, 2006. **7**(1): p. 199-205.
56. You, J., et al., Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil. *Colloids and Surfaces B: Biointerfaces*, 2006. **48**(1): p. 35-41.
57. Attama, A.A. and M.O. Nkemnele, In vitro evaluation of drug release from self-micro-emulsifying drug delivery systems using a biodegradable homolipid from *Capra hircus*. *International journal of pharmaceutics*, 2005. **304**(1-2): p. 4-10.
58. Trickler, W., A. Nagvekar, and A. Dash, A novel nanoparticle formulation for sustained paclitaxel delivery. *AAPS PharmSciTech*, 2008. **9**(2): p. 486-493.
59. Hae, G.S., et al., Enhancement of the stability of BCNU using self-emulsifying drug delivery systems (SEDDS) and in vitro antitumor activity of self-emulsified BCNU-loaded PLGA wafer. *International journal of pharmaceutics*, 2005. **301**(1- 2): p. 6-14.